How Long Can Someone Live With Kidney Failure

Pediatr Nephrol. 2017; 32(ii): 243–248.

Life expectancy with chronic kidney disease: an educational review

Guy H. Neild

UCL Middle for Nephrology, University Higher, London, NW3 2PF Great britain

Received 2022 Oct 26; Revised 2022 Mar 28; Accustomed 2022 Mar 29.

Abstract

Can renal prognosis and life expectancy be accurately predicted? Increasingly, the answer is yes. The natural history of different forms of renal affliction is becoming clearer; the caste of reduction in glomerular filtration rate (GFR) and the magnitude of proteinuria are strong predictors of renal outcome. Actuarial data on life expectancy from the start of renal replacement therapy are available from renal registries such as the U.Southward. Renal Data Arrangement (USRDS), and the Great britain Renal Registry. Recently, similar data have become available for patients with chronic kidney disease. Information collected from a large population-based registry in Alberta, Canada and stratified for dissimilar levels of estimated GFR (eGFR) accept shown that the reduction in life expectancy with kidney failure is non a uremic event associated with starting dialysis but a continuous procedure that is evident from an eGFR of ≤sixty ml/min. Even so, despite the poor prognosis of the last stages of renal failure, progress in the treatment and management of these patients and, in item, of their cardiovascular risk factors continues to better long-term outcome.

Keywords: Adolescent, Chronic kidney disease, Progressive renal failure, Life expectancy, CAKUT, End-phase kidney illness

Introduction

How much do we know almost renal prognosis and life expectancy in adolescents with chronic kidney disease (CKD)? If one sees a new patient, a 19-year-old youth with a serum creatinine level of 200 μmol/l, can one predict his likely renal prognosis and his life expectancy? The answer is yes, and this is ofttimes washed when the question is posed in a physician-legal context; however, is the respond authentic?

We know that life expectancy is much reduced with finish-phase renal failure—only what nearly the different degrees or stages of renal failure? For this review I have searched the developed and paediatric literature for papers cited in PubMed and Google Scholar that might contain data on life expectancy with CKD, or for series that have followed patients with CKD from childhood to end-stage kidney illness (ESKD) and through to renal replacement therapy (RRT). I summarise the evidence on the prediction of renal prognosis, draw of import new data from Canada that for the showtime time looks at life expectancy with different stages of CKD and cite the U.S. Renal Data System (USRDS) and Uk renal registries that written report almanac data regarding life expectancy with RRT.

Predicting renal outcome

To predict renal outcome I start make a number of assumptions. On the balance of probabilities (physician-legal language for a >l % chance), at this age (nineteen years) the patient will take some class of renal dysplasia that would fall under the full general heading of congenital anomalies of the kidney and urinary tract (CAKUT)—or some other built illness that might be tubular. If my history and examination make both of these possibilities unlikely, then further investigation is required which might include a biopsy.

If the patient has no proteinuria (protein creatinine ratio <50 mg/mmol), and so the renal function should be currently stable. Renal deterioration will not occur until at that place is increasing proteinuria [1–5]. The exception to this would be a pure tubular disease, and I am assuming that this disease will have been picked up during the history, examination and other basic investigations.

Patients with inexorably progressive renal failure tend to deteriorate at a charge per unit proportional to their proteinuria [6], but generally speaking the more proteinuria, the more than the charge per unit of progression tin be slowed past angiotensin converting enzyme inhibitors (ACEIs) and expert control of blood pressure level [2, 7–9].

Patients with pocket-size asymmetric kidneys (renal hypodysplasia—oftentimes described in the Britain as reflux nephropathy) tend to deteriorate at the slowest rates, and this is rarely greater than an estimated glomerular filtration ration (eGFR) of 3–4 ml/min/1.73 one thousand^two/year [3, vii]. Studies by of our own group have shown that controlling blood pressure level and reducing proteinuria with an ACEI should reduce the rate of loss downwardly to around 1.five ml/min/1.73 chiliad²/year [ii, 7].

Assuming that the 19-year-sometime patient with a serum creatinine level of 200 μmol/l has an eGFR of 35 ml/min/1.73 mⁱⁱ and that he volition demand dialysis when his eGFR is around 10 ml/min/1.73 m², and so he should reach ESRD in approximately 17 years [(35 − 10) divided past 1.5 years]. If he were to lose function at the faster rate of 3 ml/min/year, this would be 8.3 years.

Life expectancy with CKD

Life expectancy tables for people with CKD have been created from a large population-based registry in Alberta, Canada and stratified for dissimilar levels of eGFR [10]. Data are calculated for men and women from 30 years of age to age 85 years by their levels of kidney function as defined by eGFRs of ≥60, 45–59, 30–44 and 15–29 ml/min/1.73 chiliad² (run into Tabular array ​ i) [10]. These information show that life expectancy is progressively reduced with each age band of worse renal function.

Table one

Chronic kidney disease and life expectancy^a

Gender	Age group (year)	Kidney function (in ml/min/1.73 k2)
		eGFR ≥60	eGFR 45–59	eGFR thirty–44	eGFR 15–29
Male	thirty	39.ane (38.9–39.2)	28.4 (25.ane–31.7)	20.1 (xvi.5–23.7)	15.3 (11.0–xix.v)
	35	34.vii (34.6–34.ix)	28.0 (26.three–29.viii)	xvi.iii (thirteen.3–19.ii)	thirteen.8 (11.0–16.7)
	40	xxx.5 (30.3–thirty.6)	24.5 (23.3–25.8)	fourteen.5 (12.3–16.8)	ten.4 (8.1–12.7)
	45	26.2 (26.i–26.four)	21.3 (20.4–22.2)	12.5 (x.ix–xiv.ii)	8.8 (seven.1–10.5)
	fifty	22.iii (22.2–22.4)	18.3 (17.vii–19.0)	10.6 (9.5–11.7)	vii.four (half-dozen.1–8.seven)
	55	eighteen.6 (18.5–18.seven)	16.0 (fifteen.v–16.5)	8.7 (seven.9–9.five)	6.6 (five.6–7.half-dozen)
	60	15.one (15.0–15.2)	13.6 (thirteen.2–xiii.9)	vii.8 (7.3–eight.four)	5.half dozen (4.8–6.3)
	65	11.9 (11.8–12.0)	10.9 (x.7–xi.ii)	6.six (half-dozen.ii–7.0)	4.6 (four.2–v.one)
	70	9.0 (9.0–9.one)	viii.4 (8.3–8.half dozen)	five.9 (v.7–vi.2)	3.nine (3.6–4.2)
	75	6.vii (6.vi–vi.7)	six.ii (6.0–half-dozen.three)	four.7 (iv.5–4.9)	3.1 (2.9–iii.3)
	fourscore	4.6 (4.6–4.seven)	four.three (4.ii–iv.four)	3.4 (3.3–3.four)	two.five (2.v–2.6)
	85	ii.7 (2.5–two.8)	ii.3 (2.2–ii.5)	1.8 (1.half dozen–2.0)	one.4 (i.2–1.7)
Female	thirty	43.eight (43.vii–44.0)	33.six (31.0–36.2)	21.4 (17.three–25.5)	12.7 (vii.4–18.0)
	35	39.ii (39.0–39.3)	thirty.8 (28.ix–32.8)	17.6 (14.0–21.2)	13.1 (10.1–16.0)
	twoscore	34.6 (34.5–34.seven)	28.7 (27.5–29.9)	16.5 (14.0–19.0)	9.1 (6.half dozen–11.6)
	45	30.2 (xxx.1–xxx.iv)	25.four (24.5–26.3)	14.9 (xiii.0–16.seven)	seven.4 (5.six–9.3)
	50	26.0 (25.9–26.two)	22.3 (21.7–22.9)	13.2 (11.8–14.5)	vii.4 (5.9–8.eight)
	55	22.0 (21.9–22.1)	19.1 (18.6–19.vi)	11.three (10.3–12.3)	6.vii (five.vi–7.viii)
	60	18.ii (18.one–18.3)	sixteen.5 (16.i–16.viii)	x.half dozen (9.9–11.2)	6.ii (5.4–7.0)
	65	14.6 (14.5–fourteen.7)	thirteen.4 (13.i–13.half dozen)	9.4 (viii.9–9.9)	4.seven (4.2–5.2)
	70	eleven.iii (eleven.2–11.four)	10.5 (10.4–x.7)	7.9 (7.6–viii.ii)	4.1 (3.8–iv.5)
	75	8.4 (eight.3–8.v)	7.ix (seven.eight–eight.0)	half-dozen.0 (5.9–6.2)	three.9 (3.half dozen–four.1)
	80	5.6 (5.5–5.7)	5.3 (five.2–5.4)	four.five (4.four–4.six)	iii.ane (iii.0–3.2)
	85	3.0 (2.9–three.1)	2.8 (ii.7–2.9)	2.two (2.0–2.three)	1.6 (1.4–1.eight)

Bold our 19-twelvemonth-old patient will be alive in 11 years, when he reaches 30 (the starting historic period of the Canadian data), what tin can be expected? Looking at men age xxx–34 years (see Table ​ 1), the life expectancy for those with an eGFR of ≥60 ml/min/1.73 m² is 39.1 years. This is lower than expected and certainly much less than in the United kingdom database. For instance, data from the United kingdom predict that a normal, healthy white male anile 30 years in 2022 has a remaining expected lifetime of 50.7 years [11]. The equivalent figure for the U.s.a. suggests that for a xxx- to 34-yr-old male person the expected life expectancy is 45.vii years [12] (see Table ​ 2). The authors of this latter report explain that this divergence is attributed to the selective nature of their report cohort, which was express to individuals who had outpatient serum creatinine measurements equally part of routine care. They write that those with an eGFR of >threescore ml/min/1.73 m^two cannot exist considered as a "normal population" as patients having their creatinine measured are likely to exist less well than the full general population (who would not take a creatinine measure) and therefore have a lower life expectancy.

Table ii

Expected remaining lifetime (years) by age, sexual practice, and treatment modality of prevalent dialysis patients, prevalent transplant patients, and the general U.S. population (2012) based on USRDS data and the National Vital Statistics Study^a

	ESRD patients, 2013				Full general U.Due south. population, 2012
	Dialysis		Transplant		Male	Female
Age	Male person	Female	Male person	Female person
0–xiv	24.1	22.4	59.2	61.2	70.7	75.4
15–xix	20.9	19.3	46.8	48.vi	59.seven	64.4
xx–24	18.i	16.5	42.5	44.ii	55.0	59.5
25–29	15.8	14.3	38.6	xl.2	50.three	54.6
30–34	14.1	13.0	34.7	36.4	45.seven	49.7
35–39	12.5	11.seven	30.8	32.4	41.0	45.0
40–44	ten.viii	10.iii	26.9	28.6	36.4	40.iii
45–49	9.ane	8.viii	23.2	24.8	31.nine	35.6
fifty–54	7.7	vii.7	19.8	21.3	27.7	31.1
55–59	half-dozen.5	6.vi	16.half-dozen	18.i	23.7	26.8
threescore–64	five.5	v.7	13.8	15.2	xix.8	22.6
65–69	4.5	4.viii	11.four	12.vii	16.ii	18.5
70–74	3.viii	4.0	9.four	10.4	12.viii	xiv.7
75–79	3.2	3.5	7.7b	viii.half-dozenb	9.8	xi.3
80–84	2.6	2.9			7.1	8.4
85+	2.ane	2.4			7.9	v.eight

From Table ​ 1 it can exist seen that for the first three age groups (30–34, 35–39, 40–44 years), life expectancy falls past approximately xx % with an eGFR of 45–59 ml/min/one.73 grand², past approximately l % with an eGFR of 30–44  ml/min/1.73 mⁱⁱ and by approximately 65 % with an eGFR of 15–29 ml/min/one.73 m^two, when compared with those with an eGFR of ≥threescore ml/min/one.73 one thousand^two (note: these figures are calculated from the showtime three age groups, i.e. 30, 35 and forty years, respectively). Thus, the GFR of our patient now age thirty would be approximately 19 ml/min/one.73 m^two (eGFR decline of 1.5 ml/min/1.73 m²) and that at this level of role his life expectancy is reduced by 70 % from l.6 to 15 years.

The excess mortality associated with renal failure is due principally to the increased hazard of cardiovascular disease. An investigation of the causes of death associated with CKD in Alberta revealed that the major crusade of death was cardiovascular (including an increase in heart failure and valvular disease). The unadjusted proportion of patients who died from cardiovascular disease increased with decreasing eGFR [21, 37, 41, and 44 % of patients with an eGFR of ≥sixty (with proteinuria), 45–59.ix, 30–44.ix, and 15–29.9 ml/min/1.73 m², respectively]. The proportion of deaths from infection likewise increased but not those from cancer [13].

In a split review using meta-analysis to examine the influence of both reduced eGFR and albuminuria on cardiovascular mortality the authors establish that both lower eGFR (<60 ml/min/ane.73 m²) and higher albumin/creatinine ratio (ACR ≥10 mg/g) were independent predictors of bloodshed risk in the full general population [14]. Adjusted hazard ratios (HRs) for all-cause mortality at eGFRs of 60, 45 and 15 ml/min/ane.73 m² (vs. 95 ml/min/ane.73 mⁱⁱ) were 1.eighteen [95 % confidence interval (CI) 1.05–ane.32], i.57 (95 % CI one.39–ane.78) and 3.fourteen (95 % CI 2.39–4.xiii), respectively. The ACR was associated with bloodshed risk linearly on the log-log scale without threshold effects. Adjusted HRs for all-crusade bloodshed at ACRs of ten, 30, and 300 mg/one thousand (vs. v mg/g) were 1.20 (i.15–one.26), 1.63 (1.l–1.77) and 2.22 (1.97–2.51), respectively. These data are derived from populations a higher mean historic period, but historic period was non an independent variable.

Thus, our patient, aged 19–36, fifty-fifty with an eGFR of approximately 45 ml/min/ane.73 grand², has an increased run a risk of dying of around 57 % [risk ratio (RR) ane.57] compared with an eGFR of 95 ml/min/1.73 mⁱⁱ; similarly, with a ACR of 30 mg/g, our patient has an increased risk of dying of effectually 63 % (RR one.63) compared with ACR of 5 mg/thousand [14]. These figures correlate with life expectancy tables [10] in which a thirty-year male with an eGFR of 30–44  ml/min/1.73 m² has a life expectancy reduced by approximately 50 % compared with a like patient with an eGFR of ≥sixty  ml/min/one.73 mⁱⁱ.

To this equation we should also consider modification of life expectancy by such factors as race, gender and socio-economic status [15, 16], as well as command of blood pressure and hyperlipidemia [17]. All of these factors are beingness studied in the ongoing Chronic Kidney Disease in Children (CKiD) Study.

Predicting life expectancy at end-stage

If our patient is well looked later on for the side by side 17 years, I will assume that he will not die before he reaches ESRD at the age of 36 (age 19 + 17 years at a GFR pass up rate of ane.5 ml/min/1.73 g²/year). However, we now know that this supposition cannot be made. As we have seen from the Canadian information, even at age nineteen years with a GFR of 35 ml/min/1.73 m², we can extrapolate that his life expectancy is reduced past around 50 %. For a Uk male aged nineteen years, a life expectancy of 61.four years [11] is reduced to 30 years (age 49 years) [x].

Assuming that our patient would be around 36 years of age when stop-stage renal failure is reached, then i tin can apply two sources of actuarial information regarding future life expectancy:-

1. The USRDS Annual Written report's chapter on mortality and survival has actuarial tables which show data in v-year age bands [12] (Table ​ two). Thus, at 36 years of age, our patient falls into the historic period ring 35–39 years. This shows usa that a normal U.S. male of this age group can expect to live a farther 41 years. The same age grouping volition alive a farther 12.5 years on dialysis and thirty.eight years after a successful transplant. Of course, in reality, RRT life will tend to be a mixture of the two modes.

2. The UK Renal Registry annual report affiliate on survival also has actuarial data in 5-year age bands [18]. Withal, these show that the median life expectancy for patients starting RRT at the ninety-day time bespeak and for this age group (35–39 years) is a further xiii.five years (dialysis and transplant combined).

3. In comparison, the Canadian information prove that at age 35 years with an eGFR of 15–29 ml/min/1.73 yard², the remaining life expectancy is +thirteen.8 years [10].

Trends in life expectancy

A review of annual reports from the USRDS in the flow 1996–2013 reveals that the life expectancy for a 36-yr-former human being on haemodialysis has improved steadily and linearly from 7.2 years in 1996 to xi.5 years in 2013 (encounter Fig.1). Thus, i tin anticipate that our current projections of life expectancy probably err on the pessimistic side of reality. This is supported past a detailed analysis of paediatric outcome over the catamenia 1990–2010 [19].

Expected remaining lifetime (years) on dialysis for a 36-yr-quondam human being 1996–2013. The data in this effigy are taken from on-line archives of Usa Renal Data System (USRDS) 1996–2014[12] The interpretation and reporting of these data are the responsibility of the author and in no way should exist seen as an official policy or interpretation of the U.Southward. government

Summary and conclusions

Nosotros can now predict renal outcome and life expectancy with some accurateness, but data sources on life expectancy are few. The new information from Canada on life expectancy with CKD is very of import just will need verifying from other parts of the earth. We must not forget that collected data are often a decade old before they are analysed and published. While several long-term studies similar CKiD [xv–17] are running, it is yet as well early on for them to accept generated new data on life expectancy. However, trends in outcome continue to better, suggesting that we tin can be more optimistic than electric current data suggest.

Summary points

1. Life expectancy is reduced for all levels of renal function below an eGFR of 60 ml/min/1.73 grand².

2. Actuarial data are at present available on life expectancy both for patients with chronic kidney affliction and end-stage kidney affliction.

3. The increased take chances of premature decease is principally related to the increase in cardiovascular morbidity.

Questions (answers are provided following the reference list)

1. Proteinuria predicts progressive renal failure if greater than:

1. l mg/mmol creatinine (0.5 thou/d)

2. 100 mg/mmol creatinine (one.0 yard/d)

3. 150 mg/mmol creatinine

4. 200 mg/mmol creatinine

• 2.

  Life expectancy is reduced when eGFR falls below:

1. 60 ml/min

2. 50 ml/min

3. 50 ml/min

4. thirty ml/min

• iii.

  Life expectancy on dialysis in United states of america has stopped increasing

1. Since 2000

2. Since 2005

3. Since 2010

4. Is still increasing

• 4.

  The increased relative risk of dying in young patients with CKD is:

1. Cardiovascular

2. Cancer

3. Infection

4. None of these

Acknowledgements

Particular thanks to Retha Steenkamp and UK Renal Registry for their generous assist and advice.

Compliance with ethical standards

Conflict of interest

The writer declares no conflict of interest

Footnotes

References

1. Ardissino G, Testa Southward, Dacco 5, Vigano S, Taioli E, Claris-Appiani A, Procaccio Grand, Avolio Fifty, Ciofani A, Dello SL, Montini G. Proteinuria as a predictor of illness progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. Pediatr Nephrol. 2004;19:172–177. doi: 10.1007/s00467-003-1268-0. [PubMed] [CrossRef] [Google Scholar]

2. Neild GH, Thomson G, Nitsch D, Woolfson RG, Connolly JO, Woodhouse CR. Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys. BMC Nephrol. 2004;5:12. doi: x.1186/1471-2369-5-12. [PMC free commodity] [PubMed] [CrossRef] [Google Scholar]

iii. Gonzalez CC, Bitsori One thousand, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol. 2007;22:1014–1020. doi: 10.1007/s00467-007-0459-five. [PubMed] [CrossRef] [Google Scholar]

4. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. Lancet. 1997;349:1117–1123. doi: x.1016/S0140-6736(96)09260-4. [PubMed] [CrossRef] [Google Scholar]

5. Fathallah-Shaykh SA, Flynn JT, Pierce CB, Abraham AG, Blydt-Hansen TD, Massengill SF, Moxey-Mims MM, Warady BA, Furth SL, Wong CS. Progression of pediatric CKD of nonglomerular origin in the CKiD accomplice. Clin J Am Soc Nephrol. 2015;10:571–577. doi: 10.2215/CJN.07480714. [PMC free commodity] [PubMed] [CrossRef] [Google Scholar]

6. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN) Kidney Int. 1998;53:1209–1216. doi: ten.1046/j.1523-1755.1998.00874.x. [PubMed] [CrossRef] [Google Scholar]

7. Neild GH. What do we know about chronic renal failure in immature adults? II. Developed result of pediatric renal disease. Pediatr Nephrol. 2009;24:1921–1928. doi: 10.1007/s00467-008-1107-4. [PubMed] [CrossRef] [Google Scholar]

8. The GISEN Group Randomised placebo-controlled trial of issue of ramipril on decline in glomerular filtration rate and gamble of concluding renal failure in proteinuric, not-diabetic nephropathy. Lancet. 1997;349:1857–1863. doi: 10.1016/S0140-6736(96)11445-8. [PubMed] [CrossRef] [Google Scholar]

nine. Wuhl E, Trivelli A, Picca Southward, Litwin One thousand, Peco-Antic A, Zurowska A, Testa South, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini Thou, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter Yard, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller 1000, Wigger M, Peruzzi 50, Mehls O, Schaefer F. Strict blood-pressure control and progression of renal failure in children. Due north Engl J Med. 2009;361:1639–1650. doi: 10.1056/NEJMoa0902066. [PubMed] [CrossRef] [Google Scholar]

10. Turin TC, Tonelli G, Manns BJ, Ravani P, Ahmed SB, Hemmelgarn BR. Chronic kidney disease and life expectancy. Nephrol Punch Transplant. 2012;27:3182–3186. doi: x.1093/ndt/gfs052. [PubMed] [CrossRef] [Google Scholar]

12. The states Renal Data Organization (2015) Bloodshed. In: USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Found of Diabetes and Digestive and Kidney Diseases, Bethesda, affiliate 6, vol two, Table 6.four. Available at: http://www.usrds.org/2015/download/vol2_06_Mortality_15.pdf

13. Thompson S, James G, Wiebe Northward, Hemmelgarn B, Manns B, Klarenbach S, Tonelli Thou. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;ten:2504–2511. doi: 10.1681/ASN.2014070714. [PMC costless article] [PubMed] [CrossRef] [Google Scholar]

xiv. Matsushita K, van der Velde ABC, Woodward M, Levey Every bit, de Jong PE, Coresh J, Gansevoort RT. Clan of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular bloodshed in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort written report: a review of current findings. Am J Kidney Dis. 2012;60:1002–1011. doi: 10.1053/j.ajkd.2012.07.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

xvi. Hidalgo Thou, Ng DK, Moxey-Mims M, Minnick ML, Blydt-Hansen T, Warady BA, Furth SL. Association of income level with kidney disease severity and progression among children and adolescents with CKD: a report from the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis. 2013;62:1087–1094. doi: 10.1053/j.ajkd.2013.06.013. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth South. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) Cohort. Am J Kidney Dis. 2015;65:878–888. doi: 10.1053/j.ajkd.2015.01.008. [PMC free commodity] [PubMed] [CrossRef] [Google Scholar]

19. Mitsnefes MM, Laskin BL, Dahhou 1000, Zhang X, Foster BJ. Mortality risk among children initially treated with dialysis for terminate-phase kidney affliction, 1990–2010. JAMA. 2013;309:1921–1929. doi: 10.1001/jama.2013.4208. [PMC costless article] [PubMed] [CrossRef] [Google Scholar]

millerjecome.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203814/

Share this post